Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
By David Bienvenue, Ph.D., senior director, protein science, Bonum Therapeutics "Should we build out an internal group of scientific expertise or delegate work to external vendors?" It's a question that this author has faced in his career. He shares key considerations for building protein science teams.
By Smita Khanna, Ph.D., BioPlan Associates The continued focus on productivity and efficiency is moving manufacturers to increasingly consider outsourcing activities. Based on BioPlan Associates’ 2022 Annual Report/Survey, biomanufacturers are spending more, demanding better technologies, and expressing greater optimism. This article shares the trends in outsourced activities, percentages of activities outsourced, outsourcing destinations, and offshoring.
Article | By Patrick Stragier, Catalent In this review, we discuss a few attributes that should be considered when planning manufacturing at scale for your cell therapy. Article | By Jonathan Carson, RoosterBio While it’s well and good to track the known critical quality attributes (CQAs), this industry needs to do a better job to diminish the impact of “unknown” outputs through stringent process control over “knowns” via the process.
Newsletter | August 17, 2021 By Anthony J. Coyle, Ph.D., Repertoire Immune Medicines The potential of T-cell therapies to be curative by harnessing our own immune repertoire has exciting implications for cancer and many other immune-mediated disorders. By Erin Harris, editor in chief, Cell & Gene Many effective treatments for multiple myeloma exist, but it is currently incurable.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
